Health ❯ Healthcare ❯ Obesity

Weight Management

GLP-1 Drugs Medications GLP-1 Receptor Agonists Semaglutide Weight Loss Medications Dietary Interventions Mounjaro Medication Options Prescription Medications Weight Loss Treatments

4 ARTICLES

6d ago

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

The move pauses development of a once‑daily GLP‑1/GIP dual agonist after a 16‑week trial showed A1C reductions, meaningful weight loss, and lower insulin needs.

8 ARTICLES

3w ago

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

7 ARTICLES

last mo.

New Risk Score Predicts 10-Year Risk for 18 Obesity-Linked Diseases

6 ARTICLES

last mo.

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

8 ARTICLES

last mo.

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

10 ARTICLES

last mo.

UK Pharmacies Report Cloned Websites Pushing Fake Weight-Loss Jabs as Trade Body Urges Crackdown

4 ARTICLES

2mo ago

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

4 ARTICLES

3mo ago

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

9 ARTICLES

3mo ago

Boots Pilots First High‑Street Prescribing Service for Wegovy and Mounjaro

5 ARTICLES

4mo ago

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

9 ARTICLES

4mo ago

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

9 ARTICLES

4mo ago

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

3 ARTICLES

4mo ago

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

10 ARTICLES

4mo ago

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

5 ARTICLES

5mo ago

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

3 ARTICLES

5mo ago

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

Weight Management

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

CHMP Recommends Adding Oral Wegovy Tablets to EU Approval

New Risk Score Predicts 10-Year Risk for 18 Obesity-Linked Diseases

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

Trial Hints ‘Gut Reset’ May Slow Weight Regain After Stopping GLP‑1 Drugs

UK Pharmacies Report Cloned Websites Pushing Fake Weight-Loss Jabs as Trade Body Urges Crackdown

Studies Link GLP-1 Drugs to Lower Addiction and Overdose Risks

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

India Braces for 50+ Semaglutide Generics as Patent Expires Friday

Most Weight Lost on GLP-1 Drugs Returns After Stopping, New Analysis Finds

Never miss stories about

Weight Management

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

Boots Pilots First High‑Street Prescribing Service for Wegovy and Mounjaro

GLP-1 Weight-Loss Boom Triggers Safety Warnings and New Oversight

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

CagriSema Beats Semaglutide on HbA1c and Weight at 68 Weeks in Type 2 Diabetes Trial

UK Regulator Adds Severe Pancreatitis Warning to Ozempic, Wegovy and Mounjaro

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

Oxford BMJ Review Finds Rapid Weight Rebound After Stopping Modern Weight-Loss Drugs

Never miss stories about

Weight Management